Amneal Pharmaceuticals's revenue for the
three
months ended in Dec. 2024 was $731 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $2,794 Mil.
Amneal Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2024 was $2.36.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $8.97.
Warning Sign:
Amneal Pharmaceuticals Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Amneal Pharmaceuticals was -33.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -13.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Amneal Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 14.10% per year. The lowest was -13.10% per year. And the median was 3.90% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amneal Pharmaceuticals's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,794 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Amneal Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMRX has been successfully added to your 